SAILONG PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.19 CNY | -2.02% |
|
-4.14% | -27.06% |
| 19/04 | Sailong Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 08/04 | Sailong Pharmaceutical Group Co.,Ltd. Approves Board Elections | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,405 | 2,221 | 1,647 | 1,839 | 2,138 | 2,459 |
| Enterprise Value (EV) 1 | 2,198 | 2,203 | 1,709 | 1,899 | 2,210 | 2,507 |
| P/E ratio | 39.5 x | 81.7 x | -24.5 x | -78.8 x | -57.3 x | 258 x |
| Yield | 1.43% | 0.22% | - | - | - | - |
| Capitalization / Revenue | 5.51 x | 7.57 x | 13.7 x | 7.44 x | 8.09 x | 7.92 x |
| EV / Revenue | 5.04 x | 7.51 x | 14.2 x | 7.69 x | 8.36 x | 8.07 x |
| EV / EBITDA | 30.8 x | 58.8 x | -36 x | 360 x | -229 x | 56.3 x |
| EV / FCF | -15.1 x | -15.7 x | -40.2 x | 67.4 x | 1,053 x | -94.1 x |
| FCF Yield | -6.61% | -6.37% | -2.49% | 1.48% | 0.09% | -1.06% |
| Price to Book | 3.62 x | 3.37 x | 2.81 x | 3.26 x | 4.06 x | 4.59 x |
| Nbr of stocks (in thousands) | 1,76,000 | 1,76,000 | 1,76,000 | 1,76,000 | 1,76,000 | 1,76,000 |
| Reference price 2 | 13.66 | 12.62 | 9.360 | 10.45 | 12.15 | 13.97 |
| Announcement Date | 22/04/19 | 28/04/20 | 29/04/21 | 26/04/22 | 19/04/23 | 19/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 436.3 | 293.5 | 120.7 | 247.1 | 264.2 | 310.6 |
| EBITDA 1 | 71.39 | 37.46 | -47.46 | 5.275 | -9.667 | 44.54 |
| EBIT 1 | 57.23 | 17.49 | -76.65 | -25.99 | -42.44 | 11.65 |
| Operating Margin | 13.12% | 5.96% | -63.51% | -10.52% | -16.07% | 3.75% |
| Earnings before Tax (EBT) 1 | 70 | 32.23 | -48.83 | -13.77 | -29.67 | 22.36 |
| Net income 1 | 60.9 | 27.48 | -67.22 | -23.34 | -37.31 | 9.534 |
| Net margin | 13.96% | 9.37% | -55.7% | -9.45% | -14.12% | 3.07% |
| EPS 2 | 0.3461 | 0.1545 | -0.3819 | -0.1326 | -0.2120 | 0.0542 |
| Free Cash Flow 1 | -145.2 | -140.3 | -42.52 | 28.18 | 2.098 | -26.63 |
| FCF margin | -33.28% | -47.81% | -35.23% | 11.41% | 0.79% | -8.57% |
| FCF Conversion (EBITDA) | - | - | - | 534.28% | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1955 | 0.0273 | - | - | - | - |
| Announcement Date | 22/04/19 | 28/04/20 | 29/04/21 | 26/04/22 | 19/04/23 | 19/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 62 | 59.7 | 71.2 | 47.9 |
| Net Cash position 1 | 207 | 18 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -1.306 x | 11.32 x | -7.361 x | 1.075 x |
| Free Cash Flow 1 | -145 | -140 | -42.5 | 28.2 | 2.1 | -26.6 |
| ROE (net income / shareholders' equity) | 9.5% | 4.16% | -10.8% | -4.06% | -6.85% | 1.8% |
| ROA (Net income/ Total Assets) | 4.86% | 1.37% | -5.81% | -1.91% | -3.07% | 0.88% |
| Assets 1 | 1,252 | 2,001 | 1,158 | 1,219 | 1,217 | 1,088 |
| Book Value Per Share 2 | 3.770 | 3.740 | 3.340 | 3.200 | 2.990 | 3.040 |
| Cash Flow per Share 2 | 1.170 | 0.5500 | 0.3300 | 0.6400 | 0.4100 | 0.4900 |
| Capex 1 | 135 | 112 | 64.1 | 31.5 | 23.9 | 30.6 |
| Capex / Sales | 30.91% | 38.07% | 53.08% | 12.74% | 9.06% | 9.84% |
| Announcement Date | 22/04/19 | 28/04/20 | 29/04/21 | 26/04/22 | 19/04/23 | 19/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -27.06% | 248M | |
| +21.98% | 43.92B | |
| +24.56% | 23.09B | |
| +18.51% | 15.35B | |
| +14.03% | 13.61B | |
| +46.40% | 12.02B | |
| -10.14% | 7B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.07% | 5.6B |
- Stock Market
- Equities
- 002898 Stock
- Financials Sailong Pharmaceutical Group Co.,Ltd.
